TrianglePUBLICATIONS · 20164695
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer J
- Publication date
- 2010 Jan-Feb
- First author
- Hainsworth JD
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Hainsworth JD
- type
- Author
- name
- Spigel DR
- type
- Author
- name
- Clark BL
- type
- Author
- name
- Shipley D
- type
- Author
- name
- Thompson DS
- type
- Author
- name
- Farley C
- type
- Author
- name
- West-Osterfield K
- type
- Author
- name
- Lane CM
- type
- Author
- name
- Cescon T
- type
- Author
- name
- Bury MJ
- type
- Author
- name
- Greco FA
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Hainsworth JD
- type
- Author
- name
- Spigel DR
- type
- Author
- name
- Clark BL
- type
- Author
- name
- Shipley D
- type
- Author
- name
- Thompson DS
- type
- Author
- name
- Farley C
- type
- Author
- name
- West-Osterfield K
- type
- Author
- name
- Lane CM
- type
- Author
- name
- Cescon T
- type
- Author
- name
- Bury MJ
- type
- Author
- name
- Greco FA
- type
- Author
- bibliography ids
- nci-bib-c18a817fffb32278a7f1954e
- book metadata
- content sha256
- 9da5c66d31fa2acfec49a5c1e215979a1d0cb3e2ab9aab23bf41e06f4126fe06
- document type
- citation
- dois
- 10.1097/PPO.0b013e3181c6aa89
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:20164695
- immutable id
- pubmed:20164695@9da5c66d31fa2acfec49a5c1e215979a1d0cb3e2ab9aab23bf41e06f4126fe06
- journal
- abbreviation
- Cancer J
- issn electronic
- 1540-336X
- issn print
- 1528-9117
- issue
- 1
- name
- Cancer journal (Sudbury, Mass.)
- nlm unique id
- 100931981
- pages
- 70-5
- volume
- 16
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 20164695
- provenance
- batch id
- 708c7929ee1eff455330
- provider
- NCBI PubMed ESummary
- record sha256
- 8a46de8161c051197dfdfd6c28e9a38a731b76f6226b33137a50b9275ada72b5
- response sha256
- d245af3dbc636ffc79325b3798c7bfda16faf0a3d796681b12b8d89bd68eb450
- retrieved at
- 2026-09-09T23:46:31.496840+00:00
- publication date
- display
- 2010 Jan-Feb
- precision
- range_or_season
- year
- 2010
- publication types
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.
Preserved source evidence · Not medical advice